CA2552925A1 - Formulations pharmaceutiques a matrice semi-solide - Google Patents

Formulations pharmaceutiques a matrice semi-solide Download PDF

Info

Publication number
CA2552925A1
CA2552925A1 CA002552925A CA2552925A CA2552925A1 CA 2552925 A1 CA2552925 A1 CA 2552925A1 CA 002552925 A CA002552925 A CA 002552925A CA 2552925 A CA2552925 A CA 2552925A CA 2552925 A1 CA2552925 A1 CA 2552925A1
Authority
CA
Canada
Prior art keywords
stable pharmaceutical
dispersion according
pharmaceutical solid
semisolid dispersion
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002552925A
Other languages
English (en)
Inventor
Cristina Ciocca
Alessandro Martini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pfizer Italia S.R.L.
Cristina Ciocca
Alessandro Martini
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia S.R.L., Cristina Ciocca, Alessandro Martini, Pharmacia Italia S.P.A. filed Critical Pfizer Italia S.R.L.
Publication of CA2552925A1 publication Critical patent/CA2552925A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002552925A 2004-01-30 2004-01-30 Formulations pharmaceutiques a matrice semi-solide Abandoned CA2552925A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2004/050057 WO2005074890A1 (fr) 2004-01-30 2004-01-30 Formulations pharmaceutiques a matrice semi-solide

Publications (1)

Publication Number Publication Date
CA2552925A1 true CA2552925A1 (fr) 2005-08-18

Family

ID=34833876

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002552925A Abandoned CA2552925A1 (fr) 2004-01-30 2004-01-30 Formulations pharmaceutiques a matrice semi-solide

Country Status (4)

Country Link
EP (1) EP1713442A1 (fr)
BR (1) BRPI0418427A (fr)
CA (1) CA2552925A1 (fr)
WO (1) WO2005074890A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005314021B2 (en) 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US8377479B2 (en) * 2007-09-03 2013-02-19 Nanotherapeutics, Inc. Compositions and methods for delivery of poorly soluble drugs
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
WO2009129297A1 (fr) * 2008-04-15 2009-10-22 Schering Corporation Compositions pharmaceutiques orales semi-solides
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
WO2012063498A2 (fr) * 2010-11-12 2012-05-18 富士化学工業株式会社 Nouvelle dispersion solide d'exémestane
CN110638767B (zh) * 2019-10-12 2021-09-10 山东省食品发酵工业研究设计院 一种维生素e固体片剂及其制备方法
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
DE1015046T1 (de) * 1998-07-14 2001-02-08 Em Ind Inc Mikrodispersions-verabreichungssystem für arzneimittel
CA2471572A1 (fr) * 2001-12-28 2003-07-17 Ivax Research, Inc. Compositions a base de taxane et procedes d'utilisation

Also Published As

Publication number Publication date
BRPI0418427A (pt) 2007-06-12
EP1713442A1 (fr) 2006-10-25
WO2005074890A1 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
AU2022202259B2 (en) Novel cannabinoid formulations
US10363259B2 (en) Fulvestrant formulations
EP0977562B1 (fr) Methodes et compositions d'administration de taxanes
EP1903866B1 (fr) Administration amelioree de tetrahydrocannabinol
KR20040066921A (ko) 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
TW200302734A (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
US20040248901A1 (en) Compositions containing itraconazole and their preparation methods
JP2003512416A (ja) パクリタクセル用の新規且つ改善された組成物
EP1748756A1 (fr) Des compositions contenant drospirenone a dispersion moleculaire
JPS63165318A (ja) 光の影響に対して安定化したニフェディピン濃縮物及びその製造方法
JP2009509942A (ja) フルベストラント製剤
Nieto et al. Microencapsulation of Amorphous Solid Dispersions of Fenretinide Enhances Drug Solubility and Release from PLGA in vitro and in vivo
CN106604748A (zh) 具有改进的稳定性的含有罗替戈汀的经皮吸收制剂
US20080300322A1 (en) Delivery vehicles containing rosin resins
CA2552925A1 (fr) Formulations pharmaceutiques a matrice semi-solide
TW200906382A (en) Stable non-aqueous pour-on compositions
BRPI0619620A2 (pt) composição, uso da mesma para o tratamento e controle de infecção ou infestação endo-e ectoparasìtica em um animal homeotérmico e processo para a preparação da composição
KR20100018741A (ko) 도세탁셀 함유 항암용 주사제 조성물
KR101679380B1 (ko) 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
EP3247350A2 (fr) Formulation liquide de cabazitaxel
TW200427468A (en) Semisolid matrix pharmaceutical formulations
US20230293514A1 (en) Injectable depot formulation comprising cariprazine free base particles
MXPA02003189A (es) Formulacion antagonista de vasopresina y proceso para elaborar la misma.
KR100588810B1 (ko) 글리메피리드를 가용화시켜 투명 내용액으로 함유한연질캅셀제
CA3161080A1 (en) Biodegradable polymeric compositions, methods of preparation and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued